Stockscreener 앱 받기
0.0505
42.02%
-0.0366
전일 마감가:
$0.0871
열려 있는:
$0.0511
하루 거래량:
94,266
Relative Volume:
46.63
시가총액:
$N/A
수익:
-
순이익/손실:
$-8.67M
주가수익비율:
-0.046
EPS:
-1.0985
순현금흐름:
$-1.60M
1주 성능:
-42.02%
1개월 성능:
-42.02%
6개월 성능:
-42.02%
1년 성능:
-97.18%
1일 변동 폭
$0.05
$0.0527
1주일 범위
$0.05
$0.0527
52주 변동 폭
$0.05
$0.12
Bio Path Holdings Inc Stock (BPTH) Company Profile
Compare BPTH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.05 | 0 | 0 | -8.67M | -1.60M | -1.0985 |
VRTX
Vertex Pharmaceuticals Inc
|
438.39 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
709.98 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.81 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.46 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
314.32 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-11 | 개시 | ROTH Capital | Buy |
| 2017-11-13 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-04-18 | 개시 | Rodman & Renshaw | Buy |
| 2014-06-02 | 재개 | Maxim Group | Buy |
| 2014-05-09 | 개시 | Maxim Group | Buy |
모두보기
Bio Path Holdings Inc 주식(BPTH)의 최신 뉴스
Standex International Corporation 2026 Q1 Financial Results and SEC Filing Overview - Minichart
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path - Barchart.com
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues - Yahoo Finance
[1-K] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Leading Companies Consolidating Their Presence in the Antisense and RNAi Therapeutics Market - openPR.com
MSN Money - MSN
RNA Therapies Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Expands as 50+ - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path Holdin - Barchart.com
Layoff Tracker: Replimune lays off over 200 in Massachusetts - BioSpace
5E Advanced Materials, Inc. Files Form 8-K with Nasdaq Listing Details and Emerging Growth Company Status - Minichart
In-Depth Examination of Segments, Industry Trends, and Key - openPR.com
Microbot Medical Inc. (MBOT) stock price, news, quote and history - Yahoo Finance Australia
Stock List: Research Stocks from Around the World - GuruFocus
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Analyzing Bio-Path (BPTH) and Its Rivals - defenseworld.net
IXICO Taps Tech Bio Path with Strategic Medidata Deal - kalkinemedia.com
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
[1-A] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Shows Potential with Active Contributions from 70+ Key Companies | DelveInsight - Barchart.com
Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock - Minichart
Bio-Path Holdings approves Wyoming move and creates new preferred stock class - Investing.com Australia
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event - Stock Titan
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) - Defense World
SEC Filings for Mar 19, 202610-K, 10-Q, 8-K Forms - Stock Titan
Gossamer Bio 2025 Annual Report: Seralutinib PAH Clinical Development, FDA Path, and Regulatory Strategy Insights - Minichart
Vuzix Reports 2025 Financial Results, Secures $20M Quanta Investment, and Advances Waveguide & OEM Smart Glasses Growth - Minichart
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ - openPR.com
Is Bio Path Holdings Inc. (IBP0) stock a defensive play amid uncertaintyQuarterly Trade Review & Long Hold Capital Preservation Plans - Naître et grandir
[1-Z] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split By Investing.com - Investing.com South Africa
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split - Investing.com Australia
Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan
BPTHBio-Path Hldgs Inc Latest Stock News & Market Updates - Stock Titan
Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World
Can Bio Path Holdings Inc. (IBP0) stock surprise markets with earningsRate Cut & AI Optimized Trade Strategies - mfd.ru
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - Yahoo Finance
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working In The Domain Delveinsight - Mena FN
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Acute Myeloid Leukemia Market Forecast to 2034: 7MM - openPR.com
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer - Yahoo Finance
Antisense Oligonucleotide Therapeutics Clinical Trial - openPR.com
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Bio-Path Holdings Q3 2025: Loss of $976K, Shares at $0.07News and Statistics - IndexBox
Bio-Path: Third Quarter Financial Highlights - Bitget
Bio-Path: Q3 Earnings Snapshot - Barchart.com
BPTH: Operational pause, depleted cash, and debt defaults highlight urgent need for new funding - TradingView
BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView
Bio Path Holdings Inc (BPTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.25%
3.16%
자본화:
|
볼륨(24시간):